ERBB3 and hepatocellular carcinoma: The combination of gefitinib, which can down-regulate EGFR/HER3 expression, with sorafenib has been shown to increase tumor inhibition and prevent sorafenib resistance, demonstrating the role of EGFR/HER3 inhibition in the HCC treatment.